LambdaTest Expands KaneAI Capabilities to Elevate Testing Efficiency and Flexibility
15.11.2024 18:00:00 EET | Business Wire | Press release
LambdaTest, a leading cloud-based unified testing platform, has launched a suite of new features to KaneAI - the world’s first end-to-end software testing agent designed to streamline further and elevate the testing experience. These updates introduce expanded capabilities across web, API, and mobile app testing, making KaneAI an all-in-one solution for development and quality engineering teams aiming to optimize quality at speed.
Among the most impactful new features is the support for native app testing on Android and iOS real devices, enabling teams to test mobile applications directly within KaneAI to get automation scripts created. This addition provides greater coverage and consistency across both mobile and web environments, which is essential in today’s multi-platform landscape.
The new JavaScript Execution feature lets users add and run custom JavaScript within their web tests, providing extra control and flexibility for testing unique scenarios. With the new Scroll in Element Support, testers can now easily interact with hidden or dynamic content within specific areas of a page completely based on natural language, helping to tackle challenges in complex web layouts.
KaneAI now also includes API Testing Support, so teams can test the backend directly within the platform, ensuring that both the frontend and backend work smoothly together. Plus, the new Variables feature makes tests adaptable to different inputs from within the application, making it easier to handle various scenarios.
For teams needing to test in specific locations or environments, KaneAI also offers support for proxying traffic from different geolocations and local tunnels. This means users can mimic local conditions or test across different regions to get a better view of how the app performs worldwide.
KaneAI now makes it easier for developers by automatically creating test scripts for Selenium Java, a popular tool, which saves time on test setup. Additionally, with the new Jira Integration, teams can easily bring in test plans and cases from Jira, keeping testing and project management in sync and simplifying the workflow.
“With these recent updates, we’re revolutionizing the way teams approach testing, making it smarter and more intuitive with AI,” said Mayank Bhola, Co-Founder and Head of Products at LambdaTest. “KaneAI’s new features empower teams by simplifying the test generation process through natural language, enabling seamless creation of not only UI tests but also backend tests with JavaScript executions and comprehensive API validations. Additionally, KaneAI extends its support beyond web testing, encompassing native app tests on real mobile devices, ensuring a holistic testing experience. These advancements allow teams to deliver high-quality software faster and more efficiently, keeping their focus on what matters most.”
These updates to KaneAI make it a comprehensive testing solution for teams looking to elevate the accuracy, flexibility, and efficiency of their automation efforts. LambdaTest continues to redefine the possibilities in AI-powered test generation and automation, enabling development teams to move confidently toward faster, more reliable releases.
To learn more about these features, please visit: https://www.lambdatest.com/kane-ai
About LambdaTest
LambdaTest is an intelligent and omnichannel software quality assurance platform that enables businesses to accelerate time to market through AI-powered cloud-based test authoring, orchestration, and execution. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
- Browser & App Testing Cloud allows users to run both manual and automated tests of web and mobile apps across 5000+ different browsers, real devices, and operating system environments.
- HyperExecute helps customers run and orchestrate test grids in the cloud for any framework and programming language at blazing-fast speeds to reduce quality test time, helping developers build software faster.
For more information, please visit https://lambdatest.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241115651336/en/
Contacts
press@lambdatest.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom